UnitedHealth Group Incorporated logo

UnitedHealth Group Incorporated (UNH)

Market Closed
18 Jun, 20:00
NYSE NYSE
$
400. 96
+1.43
+0.3579%
$
373.28B Market Cap
23.04 P/E Ratio
0.16% Div Yield
11.9M Volume
22.88 Eps
$ 399.53
Previous Close
Add Transaction
Day Range
399.15 406.2
Year Range
234.6 415.98
Want to track UNH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices

UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices

The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.

Nypost | 1 year ago
UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?

UnitedHealth at 19.09X P/E: Worth the Price or Time to Take Profits?

With expansion into targeted markets and strategic diversification, UNH still has significant growth potential left.

Zacks | 1 year ago
Investors Heavily Search UnitedHealth Group Incorporated (UNH): Here is What You Need to Know

Investors Heavily Search UnitedHealth Group Incorporated (UNH): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Focus: UnitedHealth tech unit's rivals say new, post-hack customers are staying

Focus: UnitedHealth tech unit's rivals say new, post-hack customers are staying

Smaller rivals to UnitedHealth's tech unit Change Healthcare say they are signing longer-term contracts with hospitals and other customers who had temporarily switched from the company after February's cyberattack shut down the unit's services.

Reuters | 1 year ago
UnitedHealth: We See Significant Long-Term Upside

UnitedHealth: We See Significant Long-Term Upside

UnitedHealth was our top pick for 2024 due to its strong operating plan and attractive valuation. Despite trailing the S&P 500 by 11%, the stock's long-term potential remains as industry headwinds, like Medicaid and Medicare slowdowns, ease into 2025. UNH's large size and data advantages enable cost-savings and better patient outcomes, making it a strong investment amid rising competitive pressures and regulatory scrutiny.

Seekingalpha | 1 year ago
UnitedHealth Group (UNH) Stock Slides as Market Rises: Facts to Know Before You Trade

UnitedHealth Group (UNH) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, UnitedHealth Group (UNH) closed at $589.14, marking a -0.87% move from the previous day.

Zacks | 1 year ago
UnitedHealth Group: Cyberattack Is Manageable, Initiate With A 'Strong Buy'

UnitedHealth Group: Cyberattack Is Manageable, Initiate With A 'Strong Buy'

UnitedHealth's aggressive M&A strategy, including the $13 billion acquisition of Change Healthcare, has strengthened its data analytics and improved margins, justifying a 'Strong Buy' rating. Despite a major cyberattack, UnitedHealth's financial impact is manageable, with expected EPS reduction and increased CAPEX for cybersecurity enhancements. UnitedHealth's divestiture of its Brazilian business reduces FX risk, aligning with its focus on U.S. market growth driven by rising healthcare spending.

Seekingalpha | 1 year ago
What's Behind The 80% Rise In UnitedHealth Stock?

What's Behind The 80% Rise In UnitedHealth Stock?

UnitedHealth stock (NYSE: UNH) has gained 80% in value since early January 2021 – jumping from levels of $335 then to around $600 now – vs. an increase of about 45% for the S&P 500 over this period.

Forbes | 1 year ago
UnitedHealth Group: Reaches Near All-Time High But Still Looks Like A 'Buy' (Rating Upgrade)

UnitedHealth Group: Reaches Near All-Time High But Still Looks Like A 'Buy' (Rating Upgrade)

UnitedHealth Group remains a solid buy-and-hold type of stock for the long-term dividend growth investor. Shares have recently touched a new all-time high; despite that, based on earnings growth going forward, the share price doesn't look overvalued here. Consistent earnings beats could suggest that the shares are also on the cheaper end based on the fair value range, with a chance for double-digit dividend growth to continue.

Seekingalpha | 1 year ago
UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth Group said on Tuesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.

Reuters | 1 year ago
UnitedHealth Group (UNH) Stock Dips While Market Gains: Key Facts

UnitedHealth Group (UNH) Stock Dips While Market Gains: Key Facts

UnitedHealth Group (UNH) concluded the recent trading session at $594.10, signifying a -0.47% move from its prior day's close.

Zacks | 1 year ago
Why UnitedHealth Group (UNH) is a Top Stock for the Long-Term

Why UnitedHealth Group (UNH) is a Top Stock for the Long-Term

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Zacks | 1 year ago
Loading...
Load More